start-ver=1.4
cd-journal=joma
no-vol=251
cd-vols=
no-issue=
article-no=
start-page=120077
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200430
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pancreatic ductal adenocarcinoma (PDAC) is an often lethal disease characterized by a dense, fibrotic stroma. However, the lack of relevant preclinical models that recapitulate the characteristic histopathology of human PDAC in vitro impedes the development of novel therapies. The amount of stromal elements differ largely within and between patients, but in vitro models of human PDAC often do not account for this heterogeneity. Indeed, analyses of human PDAC histopathology revealed that the proportion of stroma ranged from 40 to 80% across patients. We, therefore, generated a novel 3D model of human PDAC, consisting of co-cultured human PDAC tumor cells and fibroblasts/pancreatic stellate cells, in which the proportion of fibrotic elements can be tuned across the clinically observed range. Using this model, we analyzed the signaling pathways involved in the differentiation of myofibroblasts, a characteristic subpopulation of fibroblasts seen in PDAC. We show that both YAP and SMAD2/3 in fibroblasts are required for myofibroblastic differentiation and that both shared and distinct signaling pathways regulate the nuclear localization of these factors during this process. Our novel model will be useful in promoting the understanding of the complex mechanisms by which the fibrotic stroma develops and how it might be therapeutically targeted.
en-copyright=
kn-copyright=
en-aut-name=TanakaHiroyoshi Y.
en-aut-sei=Tanaka
en-aut-mei=Hiroyoshi Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=KuriharaTsuyoshi
en-aut-sei=Kurihara
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=NakazawaTakuya
en-aut-sei=Nakazawa
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=MatsusakiMichiya
en-aut-sei=Matsusaki
en-aut-mei=Michiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MasamuneAtsushi
en-aut-sei=Masamune
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=KanoMitsunobu R.
en-aut-sei=Kano
en-aut-mei=Mitsunobu R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
affil-num=1
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
affil-num=3
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=4
en-affil=Department of Applied Chemistry, Graduate School of Engineering, Osaka University
kn-affil=
affil-num=5
en-affil=Division of Gastroenterology, Graduate School of Medicine, Tohoku University
kn-affil=
affil-num=6
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=3D culture
kn-keyword=3D culture
en-keyword=Cancer-associated fibroblast
kn-keyword=Cancer-associated fibroblast
en-keyword=Pancreatic stellate cell
kn-keyword=Pancreatic stellate cell
en-keyword=Tumor stroma
kn-keyword=Tumor stroma
en-keyword=Pancreatic cancer
kn-keyword=Pancreatic cancer
en-keyword=Myofibroblast
kn-keyword=Myofibroblast
END
start-ver=1.4
cd-journal=joma
no-vol=192
cd-vols=
no-issue=
article-no=
start-page=355
end-page=367
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2018
dt-pub=20181117
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinically relevant thickness
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Desmoplasia is a hallmark of pancreatic cancer and consists of fibrotic cells and secreted extracellular matrix (ECM) components. Various in vitro three-dimensional (3D) models of desmoplasia have been reported, but little is known about the relevant thickness of the engineered fibrotic tissue. We thus measured the thickness of fibrotic tissue in human pancreatic cancer, as defined by the distance from the blood vessel wall to tumor cells. We then generated a 3D fibrosis model with a thickness reaching the clinically observed range using pancreatic stellate cells (PSCs), the main cellular constituent of pancreatic cancer desmoplasia. Using this model, we found that Collagen fiber deposition was increased and Fibronectin fibril orientation drastically remodeled by PSCs, but not normal fibroblasts, in a manner dependent on Transforming Growth Factor (TGF)-β/Rho-Associated Kinase (ROCK) signaling and Matrix Metalloproteinase (MMP) activity. Finally, by targeting Secreted Protein, Acidic and Rich in Cysteine (SPARC) by siRNA, we found that SPARC expression in PSCs was necessary for ECM remodeling. Taken together, we developed a 3D fibrosis model of pancreatic cancer with a clinically relevant thickness and observed aberrant SPARC-dependent ECM remodeling in cancer-derived PSCs.
en-copyright=
kn-copyright=
en-aut-name=TanakaHiroyoshi Y.
en-aut-sei=Tanaka
en-aut-mei=Hiroyoshi Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=KitaharaKentaro
en-aut-sei=Kitahara
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=SasakiNaoki
en-aut-sei=Sasaki
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NakaoNatsumi
en-aut-sei=Nakao
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=SatoKae
en-aut-sei=Sato
en-aut-mei=Kae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=NaritaHirokazu
en-aut-sei=Narita
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=ShimodaHiroshi
en-aut-sei=Shimoda
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MatsusakiMichiya
en-aut-sei=Matsusaki
en-aut-mei=Michiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=NishiharaHiroshi
en-aut-sei=Nishihara
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=MasamuneAtsushi
en-aut-sei=Masamune
en-aut-mei=Atsushi
kn-aut-name=Atsushi Masamune
kn-aut-sei=Atsushi Masamune
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=KanoMitsunobu R.
en-aut-sei=Kano
en-aut-mei=Mitsunobu R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
affil-num=1
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of Chemical and Biological Sciences, Japan Women's University
kn-affil=
affil-num=4
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=5
en-affil=Department of Chemical and Biological Sciences, Japan Women's University
kn-affil=
affil-num=6
en-affil=Department of Anatomical Science, Hirosaki University Graduate School of Medicine
kn-affil=
affil-num=7
en-affil=Department of Anatomical Science, Hirosaki University Graduate School of Medicine
kn-affil=
affil-num=8
en-affil=Department of Frontier Biosciences, Osaka University Graduate School of Frontier Biosciences
kn-affil=
affil-num=9
en-affil=Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Institute of Integrated Medical Research
kn-affil=
affil-num=10
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=
affil-num=11
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Fibrosis
kn-keyword=Fibrosis
en-keyword=Extracellular matrix remodeling
kn-keyword=Extracellular matrix remodeling
en-keyword=3D culture
kn-keyword=3D culture
en-keyword=Pancreatic stellate cell
kn-keyword=Pancreatic stellate cell
en-keyword=SPARC
kn-keyword=SPARC
END
start-ver=1.4
cd-journal=joma
no-vol=230
cd-vols=
no-issue=
article-no=
start-page=109
end-page=115
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=20160528
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pancreatic cancer is notorious for its poor prognosis. The histopathologic characteristic of pancreatic ductal adenocarcinoma (PDAC), which is the most common type of pancreatic cancer, is fibrosis within tumor tissue. Although fibrosis within tumor tissue is thought to impede drug therapy by interfering with the intratumoral accumulation of anti-tumor drugs, this hypothesis has yet to be proven directly in preclinical models. Here, we evaluated the effect of enhanced fibrosis on intratumoral accumulation of macromolecular drugs by increasing fibrosis in a murine tumor model of subcutaneously xenografted BxPC-3, a human PDAC cell line. When fibroblast growth factor-2 (FGF-2) was co-administered upon BxPC-3 inoculation, stromal fibrotic area was increased and was characterized by augmented murine collagen accumulation compared to inoculation of BxPC-3 alone, which correlated with increased monocyte/macrophage contents in the tumor tissues. We further discovered that the intratumoral accumulation of intravenously administrated fluorescein isothiocyanate-dextran of 2,000,000 Da (2 MDa) was significantly reduced in the FGF-2 co-administered tumors despite unaltered hyaluronan accumulation and pericyte coverage of the tumor neovasculature and increased lymphangiogenesis. Finally, we found that FGF-2 co-administered tumors are more refractory to macromolecular drug therapy using nab-paclitaxel (Abraxane). The model established and analyzed in this study, characterized by increased fibrotic component, provides a preclinical animal model suited to predict the intratumoral accumulation of macromolecular drugs and to evaluate the efficacy of drugs targeting the tumor stroma.
en-copyright=
kn-copyright=
en-aut-name=SakaiSatoshi
en-aut-sei=Sakai
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IwataCaname
en-aut-sei=Iwata
en-aut-mei=Caname
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=TanakaHiroyoshi Y.
en-aut-sei=Tanaka
en-aut-mei=Hiroyoshi Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=CabralHoracio
en-aut-sei=Cabral
en-aut-mei=Horacio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MorishitaYasuyuki
en-aut-sei=Morishita
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MiyazonKohei
en-aut-sei=Miyazon
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=KanoMitsunobu R.
en-aut-sei=Kano
en-aut-mei=Mitsunobu R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
affil-num=1
en-affil=Graduate School of Medicine, The University of Tokyo
kn-affil=
affil-num=2
en-affil=Graduate School of Medicine, The University of Tokyo
kn-affil=
affil-num=3
en-affil= Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=4
en-affil=Graduate School of Engineering, The University of Tokyo
kn-affil=
affil-num=5
en-affil=Graduate School of Medicine, The University of Tokyo
kn-affil=
affil-num=6
en-affil=Graduate School of Medicine, The University of Tokyo
kn-affil=
affil-num=7
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Macromolecular drugs
kn-keyword=Macromolecular drugs
en-keyword=Drug distribution
kn-keyword=Drug distribution
en-keyword=Pancreatic ductal adenocarcinoma
kn-keyword=Pancreatic ductal adenocarcinoma
en-keyword=Fibrosis
kn-keyword=Fibrosis
en-keyword=FGF-2
kn-keyword=FGF-2
END
start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=12
article-no=
start-page=e033462
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=20191211
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Fall-related mortality trends in older Japanese adults aged >= 65 years: a nationwide observational study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=OBJECTIVES:
Fall-related mortality among older adults is a major public health issue, especially for ageing societies. This study aimed to investigate current trends in fall-related mortality in Japan using nationwide population-based data covering 1997-2016.
DESIGN:
We analysed fall-related deaths among older persons aged ≥65 years using the data provided by the Japanese Ministry of Health, Labour and Welfare.
RESULTS:
The crude and age-standardised mortality rates were calculated per 100 000 persons by stratifying by age (65-74, 75-84 and ≥85 years) and sex. To identify trend changes, a joinpoint regression model was applied by estimating change points and annual percentage change (APC). The total number of fall-related deaths in Japan increased from 5872 in 1997 to 8030 in 2016, of which 78.8% involved persons aged ≥65 years. The younger population (65-74 years) showed continuous and faster-decreasing trends for both men and women. Average APC among men aged ≥75 years did not decrease. Among middle-aged and older women (75-84 and ≥85 years) decreasing trends were observed. Furthermore, the age-adjusted mortality rate of men was approximately twice that of women, and it showed a faster decrease for women.
CONCLUSIONS:
Although Japanese healthcare has shown improvement in preventing fall-related deaths over the last two decades, the crude mortality for those aged over 85 years remains high, indicating difficulty in reducing fall-related deaths in the super-aged population. Further investigations to uncover causal factors for falls in older populations are required.
en-copyright=
kn-copyright=
en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=TatebeYasuhisa
en-aut-sei=Tatebe
en-aut-mei=Yasuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=FunahashiTomoko
en-aut-sei=Funahashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=ShinomiyaKazuaki
en-aut-sei=Shinomiya
en-aut-mei=Kazuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=RakugiHiromi
en-aut-sei=Rakugi
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=KanoMitsunobu R.
en-aut-sei=Kano
en-aut-mei=Mitsunobu R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
affil-num=1
en-affil=Department of General Internal Medicine, Osaka University Hospital
kn-affil=
affil-num=2
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School
kn-affil=
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
affil-num=6
en-affil=Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences Tokushima Bunri University
kn-affil=
affil-num=7
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Department of Biostatistics, Sapporo Medical University
kn-affil=
affil-num=9
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=10
en-affil=Department of General Internal Medicine, Osaka University Hospital
kn-affil=
affil-num=11
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
en-keyword=adult intensive & critical care
kn-keyword=adult intensive & critical care
en-keyword=epidemiology
kn-keyword=epidemiology
en-keyword=geriatric medicine
kn-keyword=geriatric medicine
en-keyword=health & safety
kn-keyword=health & safety
en-keyword=health policy
kn-keyword=health policy
en-keyword=public health
kn-keyword=public health
END
start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=
article-no=
start-page=20235
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2019
dt-pub=20191227
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Place of death trends among patients with dementia in Japan: a population-based observational study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Dementia is a major public health concern in ageing societies. Although the population of Japan is among the most aged worldwide, long-term trends in the place of death (PoD) among patients with dementia is unknown. In this Japanese nationwide observational study, we analysed trends in PoD using the data of patients with dementia who were aged >= 65 years and died during 1999-2016. Trends in the crude death rates and PoD frequencies were analysed using the Joinpoint regression model. Changes in these trends were assessed using the Joinpoint regression analysis in which significant change points, the annual percentage change (APC) and average APCs (AAPC) in hospitals, homes, or nursing homes were estimated. During 1999-2016, the number of deaths among patients with dementia increased from 3,235 to 23,757 (total: 182,000). A trend analysis revealed increased mortality rates, with an AAPC of 8.2% among men and 9.3% among women. Most patients with dementia died in the hospital, although the prevalence of hospital deaths decreased (AAPC: -1.0%). Moreover, the prevalence of nursing home deaths increased (AAPC: 5.6%), whereas the prevalence of home deaths decreased (AAPC: -5.8%). These findings support a reconsideration of the end-of-life care provided to patients with dementia.
en-copyright=
kn-copyright=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=SasakiMisato
en-aut-sei=Sasaki
en-aut-mei=Misato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=FunahashiTomoko
en-aut-sei=Funahashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=OhshimaAyako
en-aut-sei=Ohshima
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=TatebeYasuhisa
en-aut-sei=Tatebe
en-aut-mei=Yasuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MikamiNaoko
en-aut-sei=Mikami
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=ShinomiyaKazuaki
en-aut-sei=Shinomiya
en-aut-mei=Kazuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=KanoMitsunobu R.
en-aut-sei=Kano
en-aut-mei=Mitsunobu R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
affil-num=1
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=4
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School
kn-affil=
affil-num=5
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
affil-num=6
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=7
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Division of Pharmacy, Chiba University Hospital
kn-affil=
affil-num=9
en-affil=Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University
kn-affil=
affil-num=10
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=11
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=12
en-affil=Department of Biostatistics, Sapporo Medical University
kn-affil=
affil-num=13
en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
END